Pre-treatment: Measure morning resting heart rate for 5 days Calculate average baseline Record any existing caffeine or stimulant use During treatment: Measure resting heart rate 3 times weekly during dose escalation Continue at each dose for minimum 4 weeks before increasing If resting HR exceeds baseline by more than 15 BPM, hold dose for an additional 2 weeks If resting HR exceeds 100 BPM at rest on two or more measurements, consult physician Expected timeline: Weeks 1-8: minimal heart rate change at starting doses Weeks 8-24: gradual increase of 5-10 BPM at therapeutic doses Weeks 24+: stabilization and gradual decline toward baseline This is the approach most researchers follow successfully, and it aligns with the standard retatrutide dosing protocol used in clinical trials
Mild side effects may include nausea, stomach upset, or headaches in some individuals
Nat Rev Cardiol
The rationale is straightforward: a 120kg individual has significantly more tissue volume for the peptide to distribute through than a 70kg individual, which affects both the effective concentration at receptor sites and the perceived intensity of side effects
Furthermore, the SGLT2i group demonstrated a significantly lower risk of composite surgical outcome (SHR, 0.58
Advantage : Neither (tie) Weight Loss Efficacy# Orforglipron : ATTAIN-1 demonstrated 12.4% mean weight loss at 36 mg over 72 weeks (efficacy estimand)